News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,053 Results
Type
Article (45291)
Company Profile (278)
Press Release (691474)
Multimedia
Podcasts (90)
Webinars (18)
Section
Business (207148)
Career Advice (2153)
Deals (35773)
Drug Delivery (116)
Drug Development (83104)
Employer Resources (176)
FDA (16678)
Job Trends (15192)
News (351406)
Policy (33518)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2764)
Accelerated approval (32)
Adcomms (26)
Allergies (144)
Alliances (50346)
ALS (171)
Alzheimer's disease (1718)
Antibody-drug conjugate (ADC) (318)
Approvals (16923)
Artificial intelligence (524)
Autoimmune disease (153)
Automation (38)
Bankruptcy (364)
Best Places to Work (11823)
BIOSECURE Act (20)
Biosimilars (189)
Biotechnology (178)
Bladder cancer (160)
Brain cancer (56)
Breast cancer (641)
Cancer (4859)
Cardiovascular disease (412)
Career advice (1811)
Career pathing (37)
CAR-T (284)
CDC (49)
Celiac Disease (2)
Cell therapy (751)
Cervical cancer (36)
Clinical research (70803)
Collaboration (1727)
Company closure (4)
Compensation (1163)
Complete response letters (59)
COVID-19 (2769)
CRISPR (89)
C-suite (848)
Cystic fibrosis (143)
Data (6264)
Decentralized trials (2)
Denatured (25)
Depression (135)
Diabetes (518)
Diagnostics (6785)
Digital health (48)
Diversity (12)
Diversity, equity & inclusion (46)
Drug discovery (255)
Drug pricing (192)
Drug shortages (30)
Duchenne muscular dystrophy (239)
Earnings (90360)
Editorial (58)
Employer branding (21)
Employer resources (154)
Events (119718)
Executive appointments (977)
FDA (19804)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1482)
Gene editing (196)
Generative AI (45)
Gene therapy (615)
GLP-1 (1019)
Government (4840)
Grass and pollen (7)
Guidances (383)
Healthcare (19366)
HIV (59)
Huntington's disease (45)
IgA nephropathy (83)
Immunology and inflammation (255)
Immuno-oncology (59)
Indications (109)
Infectious disease (3046)
Inflammatory bowel disease (188)
Inflation Reduction Act (14)
Influenza (115)
Intellectual property (251)
Interviews (342)
IPO (16723)
IRA (53)
Job creations (3705)
Job search strategy (1522)
JPM (58)
Kidney cancer (16)
Labor market (85)
Layoffs (563)
Leadership (32)
Legal (8140)
Liver cancer (92)
Longevity (14)
Lung cancer (655)
Lymphoma (377)
Machine learning (42)
Management (60)
Manufacturing (793)
MASH (175)
Medical device (13944)
Medtech (13997)
Mergers & acquisitions (20127)
Metabolic disorders (1319)
Multiple sclerosis (163)
NASH (20)
Neurodegenerative disease (323)
Neuropsychiatric disorders (89)
Neuroscience (2975)
Neurotech (1)
NextGen: Class of 2026 (6735)
Non-profit (4693)
Now hiring (67)
Obesity (623)
Opinion (269)
Ovarian cancer (168)
Pain (203)
Pancreatic cancer (230)
Parkinson's disease (289)
Partnered (33)
Patents (497)
Patient recruitment (496)
Peanut (57)
People (59972)
Pharmaceutical (64)
Pharmacy benefit managers (30)
Phase 1 (22082)
Phase 2 (31159)
Phase 3 (23171)
Pipeline (5276)
Policy (296)
Postmarket research (2677)
Preclinical (9454)
Press Release (68)
Prostate cancer (241)
Psychedelics (49)
Radiopharmaceuticals (281)
Rare diseases (850)
Real estate (6049)
Recruiting (71)
Regulatory (24966)
Reports (52)
Research institute (2508)
Resumes & cover letters (369)
Rett syndrome (27)
RNA editing (17)
RSV (80)
Schizophrenia (152)
Series A (241)
Series B (190)
Service/supplier (12)
Sickle cell disease (97)
Special edition (21)
Spinal muscular atrophy (163)
Sponsored (42)
Startups (3695)
State (2)
Stomach cancer (18)
Supply chain (105)
Tariffs (85)
The Weekly (63)
Vaccines (1038)
Venture capital (90)
Weight loss (405)
Women's health (89)
Worklife (20)
Date
Today (153)
Last 7 days (577)
Last 30 days (2103)
Last 365 days (30262)
2026 (3348)
2025 (30524)
2024 (35648)
2023 (40539)
2022 (51709)
2021 (56271)
2020 (54814)
2019 (47620)
2018 (35904)
2017 (32736)
2016 (32309)
2015 (38369)
2014 (32121)
2013 (27275)
2012 (29434)
2011 (30128)
2010 (28282)
Location
Africa (771)
Alabama (83)
Alaska (7)
Arizona (311)
Arkansas (14)
Asia (40064)
Australia (6669)
California (11314)
Canada (3292)
China (1109)
Colorado (480)
Connecticut (477)
Delaware (336)
Europe (87566)
Florida (1687)
Georgia (358)
Hawaii (3)
Idaho (63)
Illinois (874)
India (65)
Indiana (523)
Iowa (23)
Japan (428)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1383)
Massachusetts (8133)
Michigan (326)
Minnesota (630)
Mississippi (6)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (80)
New Jersey (3013)
New Mexico (29)
New York (2996)
North Carolina (1473)
North Dakota (9)
Northern California (5528)
Ohio (334)
Oklahoma (21)
Oregon (44)
Pennsylvania (2284)
Puerto Rico (25)
Rhode Island (47)
South America (1165)
South Carolina (67)
South Dakota (1)
Southern California (4397)
Tennessee (177)
Texas (1745)
United States (40211)
Utah (338)
Vermont (1)
Virginia (264)
Washington D.C. (84)
Washington State (940)
West Virginia (4)
Wisconsin (108)
Wyoming (2)
737,053 Results for "ccs associates inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CCS Presents Four Peer-Reviewed Posters at American Diabetes Association’s 85th Scientific Sessions
June 23, 2025
·
4 min read
Press Releases
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
November 20, 2025
·
10 min read
Press Releases
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
December 19, 2025
·
4 min read
BioForest
Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO
At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.
March 11, 2024
·
6 min read
Press Releases
Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy
December 15, 2025
·
4 min read
BioForest
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
Cocrystal Pharma, Inc. announces it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA) regarding CC-42344 as a potential oral treatment for pandemic and seasonal influenza A.
March 19, 2024
·
5 min read
Press Releases
Pramana Pharmaceuticals Awarded USD $1 Million from the Alzheimer’s Association
January 8, 2026
·
2 min read
Press Releases
Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
November 6, 2025
·
5 min read
Press Releases
Precisio Biotix Therapeutics, Inc. (Precisio) Announces a Grant for the Discovery of Novel Engineered Lysin Antimicrobials Targeting Bacterial Vaginosis Associated Pathobionts (BV)
June 16, 2025
·
3 min read
Drug Development
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
Cocrystal Pharma, Inc. announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344.
May 1, 2024
·
5 min read
1 of 73,706
Next
